Tolbutamide, K+ channel blocker (ab120278)
Key features and details
- K+ channel blocker
- CAS Number: 64-77-7
- Soluble in DMSO to 100 mM and in ethanol to 100 mM
- Form / State: Solid
- Source: Synthetic
Overview
-
Product name
Tolbutamide, K+ channel blocker -
Description
K+ channel blocker -
Biological description
Blocker of ATP-sensitive (KIR6.x) inward rectifier K+ channels.
-
CAS Number
64-77-7 -
Chemical structure
Properties
-
Chemical name
1-Butyl-3-tosylurea -
Molecular weight
270.35 -
Molecular formula
C12H18N2O3S -
PubChem identifier
5505 -
Storage instructions
Store at Room Temperature. The product can be stored for up to 12 months. -
Solubility overview
Soluble in DMSO to 100 mM and in ethanol to 100 mM -
Handling
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Refer to SDS for further information.
Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.
-
SMILES
Cc1ccc(cc1)S(=O)(=O)NC(=O)NCCCC -
Source
Synthetic
-
Research areas
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab120278 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
Functional Studies |
Use at an assay dependent concentration.
|
Notes |
---|
Functional Studies
Use at an assay dependent concentration. |
Images
-
2D chemical structure image of ab120278, Tolbutamide, K+ channel blocker
-
U-87 MG cells were incubated at 37°C for 30 minutes with vehicle control (0 µM) and 200 µM of tolbutamide (ab120278) in DMSO. Increased expression of hexokinase type II (ab70360) correlates with an increase in tolbutamide concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab70360 at 2 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
References (1)
ab120278 has been referenced in 1 publication.
- González BJ et al. Reduced calcium levels and accumulation of abnormal insulin granules in stem cell models of HNF1A deficiency. Commun Biol 5:779 (2022). PubMed: 35918471